The COVID-19 pandemic in Portugal: Evolution, Vaccination and Pharmacovigilance
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | https://doi.org/10.23882/rmd.22090 |
Resumo: | The disease caused by the new SARS-CoV-2 virus (COVID-19) was first reported in December 2019 in Wuhan, China, and subsequently it spread throughout the world.On March 2, 2020, the first two cases of COVID-19 were confirmed in Portuguese territory, with the first death to be registered two weeks later, on March 16. Thereafter, a wide and variable set of sanitary measures were applied, as well as the publication of norms and guidelines by the Directorate-General of Health (DGS) and by the National Authority of Medicines and Health Products, I.P. (INFARMED). Later, on December 27, 2020, the first vaccine against COVID-19 (Comirnaty®; BioNTech Manufacturing GmbH/Pfizer) was administered at the University Hospital Centre of São João, in Porto, marking the beginning of the defined vaccination plan by the task-force and the involvement of different health professionals.Pharmacovigilance of vaccines against COVID-19 is an area of enormous importance, through the generation of real-world evidence on post-marketing safety and effectiveness. The Pharmacovigilance Systems are responsible for receiving, validating, analysing, requesting additional data, codifying and collaborating in the attribution of causality to all suspected adverse reactions.The aim of this article is to portray the COVID-19 pandemic in Portugal, with regard to its evolution, vaccination plan and Pharmacovigilance activities. Additionally, the issue is articulated with the international reality, highlighting the main measures, stakeholders and impact on public health. |
id |
RCAP_a57dc04c07903d2b2dcdeeb7b6dd44ab |
---|---|
oai_identifier_str |
oai:ojs2.revistamultidisciplinar.com:article/90 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
The COVID-19 pandemic in Portugal: Evolution, Vaccination and PharmacovigilanceA pandemia de COVID-19 em Portugal: Evolução, Vacinação e FarmacovigilânciaPandemiaCOVID-19PortugalVacinaçãoFarmacovigilânciaPandemicCOVID-19PortugalVaccinationPharmacovigilanceThe disease caused by the new SARS-CoV-2 virus (COVID-19) was first reported in December 2019 in Wuhan, China, and subsequently it spread throughout the world.On March 2, 2020, the first two cases of COVID-19 were confirmed in Portuguese territory, with the first death to be registered two weeks later, on March 16. Thereafter, a wide and variable set of sanitary measures were applied, as well as the publication of norms and guidelines by the Directorate-General of Health (DGS) and by the National Authority of Medicines and Health Products, I.P. (INFARMED). Later, on December 27, 2020, the first vaccine against COVID-19 (Comirnaty®; BioNTech Manufacturing GmbH/Pfizer) was administered at the University Hospital Centre of São João, in Porto, marking the beginning of the defined vaccination plan by the task-force and the involvement of different health professionals.Pharmacovigilance of vaccines against COVID-19 is an area of enormous importance, through the generation of real-world evidence on post-marketing safety and effectiveness. The Pharmacovigilance Systems are responsible for receiving, validating, analysing, requesting additional data, codifying and collaborating in the attribution of causality to all suspected adverse reactions.The aim of this article is to portray the COVID-19 pandemic in Portugal, with regard to its evolution, vaccination plan and Pharmacovigilance activities. Additionally, the issue is articulated with the international reality, highlighting the main measures, stakeholders and impact on public health.A doença provocada pelo novo vírus SARS-CoV-2 (COVID-19) foi relatada pela primeira vez em dezembro de 2019, em Wuhan, China, e posteriormente disseminou-se por todo o mundo.A 2 de março de 2020, foram confirmados os primeiros dois casos de COVID-19 em território português, com a primeira morte a ser registada duas semanas depois, a 16 de março. Daí em diante, um conjunto alargado e variável de medidas sanitárias foram aplicadas, assim como a publicação de normas e orientações pela Direção-Geral da Saúde (DGS) e pela Autoridade Nacional do Medicamento e Produtos de Saúde, I.P. (INFARMED). Posteriormente, a 27 de dezembro de 2020, foi administrada a primeira vacina contra a COVID-19 (Comirnaty®; BioNTech Manufacturing GmbH/Pfizer), no Centro Hospitalar Universitário de São João, no Porto, marcando o início do plano de vacinação definido pela task-force e o envolvimento dos diversos profissionais de saúde.A Farmacovigilância das vacinas contra a COVID-19 constitui uma área de enorme importância, através da geração de evidência de mundo real sobre a segurança e efetividade pós-comercialização. Os Sistemas de Farmacovigilância têm a responsabilidade de rececionar, validar, analisar, solicitar dados adicionais, codificar e colaborar na imputação de causalidade de todas as suspeitas de reações adversas.Este artigo retrata a pandemia de COVID-19 em Portugal, no que concerne à sua evolução, plano de vacinação e atividades de Farmacovigilância. Adicionalmente, articula-se o tema com a realidade internacional, evidenciando-se as principais medidas, intervenientes e impacto na saúde pública.NMd, Núcleo Multidisiplinar2022-02-20info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdftext/htmlhttps://doi.org/10.23882/rmd.22090https://doi.org/10.23882/rmd.22090Multidisciplinary Journal; Vol. 4 No. 2 (2022): History of Science and Pandemics; 135-154RevistaMultidisciplinar; Vol. 4 Núm. 2 (2022): História da Ciência e as Pandemias; 135-154Revue Multidisciplinaire; Vol. 4 No 2 (2022): História da Ciência e as Pandemias; 135-154RevistaMultidisciplinar; Vol. 4 N.º 2 (2022): História da Ciência e as Pandemias; 135-1542184-549210.23882/rmd.v4n2reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://revistamultidisciplinar.com/index.php/oj/article/view/90https://revistamultidisciplinar.com/index.php/oj/article/view/90/120https://revistamultidisciplinar.com/index.php/oj/article/view/90/128Direitos de Autor (c) 2022 Renato Ferreira da Silva, Mário Macedo, Jaime Conceiçãoinfo:eu-repo/semantics/openAccessFerreira da Silva, RenatoMacedo, MárioConceição, Jaime2022-12-31T07:00:28Zoai:ojs2.revistamultidisciplinar.com:article/90Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T15:48:33.670089Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
The COVID-19 pandemic in Portugal: Evolution, Vaccination and Pharmacovigilance A pandemia de COVID-19 em Portugal: Evolução, Vacinação e Farmacovigilância |
title |
The COVID-19 pandemic in Portugal: Evolution, Vaccination and Pharmacovigilance |
spellingShingle |
The COVID-19 pandemic in Portugal: Evolution, Vaccination and Pharmacovigilance Ferreira da Silva, Renato Pandemia COVID-19 Portugal Vacinação Farmacovigilância Pandemic COVID-19 Portugal Vaccination Pharmacovigilance |
title_short |
The COVID-19 pandemic in Portugal: Evolution, Vaccination and Pharmacovigilance |
title_full |
The COVID-19 pandemic in Portugal: Evolution, Vaccination and Pharmacovigilance |
title_fullStr |
The COVID-19 pandemic in Portugal: Evolution, Vaccination and Pharmacovigilance |
title_full_unstemmed |
The COVID-19 pandemic in Portugal: Evolution, Vaccination and Pharmacovigilance |
title_sort |
The COVID-19 pandemic in Portugal: Evolution, Vaccination and Pharmacovigilance |
author |
Ferreira da Silva, Renato |
author_facet |
Ferreira da Silva, Renato Macedo, Mário Conceição, Jaime |
author_role |
author |
author2 |
Macedo, Mário Conceição, Jaime |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Ferreira da Silva, Renato Macedo, Mário Conceição, Jaime |
dc.subject.por.fl_str_mv |
Pandemia COVID-19 Portugal Vacinação Farmacovigilância Pandemic COVID-19 Portugal Vaccination Pharmacovigilance |
topic |
Pandemia COVID-19 Portugal Vacinação Farmacovigilância Pandemic COVID-19 Portugal Vaccination Pharmacovigilance |
description |
The disease caused by the new SARS-CoV-2 virus (COVID-19) was first reported in December 2019 in Wuhan, China, and subsequently it spread throughout the world.On March 2, 2020, the first two cases of COVID-19 were confirmed in Portuguese territory, with the first death to be registered two weeks later, on March 16. Thereafter, a wide and variable set of sanitary measures were applied, as well as the publication of norms and guidelines by the Directorate-General of Health (DGS) and by the National Authority of Medicines and Health Products, I.P. (INFARMED). Later, on December 27, 2020, the first vaccine against COVID-19 (Comirnaty®; BioNTech Manufacturing GmbH/Pfizer) was administered at the University Hospital Centre of São João, in Porto, marking the beginning of the defined vaccination plan by the task-force and the involvement of different health professionals.Pharmacovigilance of vaccines against COVID-19 is an area of enormous importance, through the generation of real-world evidence on post-marketing safety and effectiveness. The Pharmacovigilance Systems are responsible for receiving, validating, analysing, requesting additional data, codifying and collaborating in the attribution of causality to all suspected adverse reactions.The aim of this article is to portray the COVID-19 pandemic in Portugal, with regard to its evolution, vaccination plan and Pharmacovigilance activities. Additionally, the issue is articulated with the international reality, highlighting the main measures, stakeholders and impact on public health. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-02-20 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.23882/rmd.22090 https://doi.org/10.23882/rmd.22090 |
url |
https://doi.org/10.23882/rmd.22090 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://revistamultidisciplinar.com/index.php/oj/article/view/90 https://revistamultidisciplinar.com/index.php/oj/article/view/90/120 https://revistamultidisciplinar.com/index.php/oj/article/view/90/128 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2022 Renato Ferreira da Silva, Mário Macedo, Jaime Conceição info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2022 Renato Ferreira da Silva, Mário Macedo, Jaime Conceição |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf text/html |
dc.publisher.none.fl_str_mv |
NMd, Núcleo Multidisiplinar |
publisher.none.fl_str_mv |
NMd, Núcleo Multidisiplinar |
dc.source.none.fl_str_mv |
Multidisciplinary Journal; Vol. 4 No. 2 (2022): History of Science and Pandemics; 135-154 RevistaMultidisciplinar; Vol. 4 Núm. 2 (2022): História da Ciência e as Pandemias; 135-154 Revue Multidisciplinaire; Vol. 4 No 2 (2022): História da Ciência e as Pandemias; 135-154 RevistaMultidisciplinar; Vol. 4 N.º 2 (2022): História da Ciência e as Pandemias; 135-154 2184-5492 10.23882/rmd.v4n2 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799130351630548992 |